Furthermore, the addition of systemic PD-1 or TIM-3 blockade to CAR-T cell treatment resulted in a synergistic anti-tumor activity suggesting TIM-3 blockade may useful in conjunction with CAR-T therapy. Here, PDCD1 is linked to neoplasm.